logo

For the Inventor, By the Inventor

San Francisco, CA, United States of America

Demetrios P Papahadjopoulos

This inventor holds 21 USPTO granted patents and 1 EPO patent, primarily in Lipid Nanotechnology. Top assignees: University of California, Other. Active years: 1980-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Demetrios P Papahadjopoulos. Retrieved from https://idiyas.com/inventor/demetrios-p-papahadjopoulos

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21

% Patents Active = 85.7


Average Co-Inventor Count = 2.9

ph-index = 15

Forward Citations = 2,194(Granted Patents)


Location History:

  • Williamsville, NY (US) (1980)
  • Lafayette, CA (US) (1983 - 1989)
  • late of San Francisco, CA (US) (2002)
  • San Francisco, CA (US) (1986 - 2011)

Company Filing History:

goldMedal17 out of 16,035 
 
University of California
 patents
silverMedal4 out of 834,570 
Other
 patents

Years Active: 1980-2011

Loading Chart...
Loading Chart...
Areas of Expertise:
Immunoliposomes
Lipid-Nucleic Acid Complexes
Protein Attachment
Microparticles
In Vivo Delivery
pH-Sensitive Liposomes
Cell Internalization
Biologically Active Materials
Diagnostic Methods
Antigen Conjugation
Thiol Reactive Liposomes
Plant Nutriment Compositions
21 patents (USPTO):Explore Patents
1. 7871620 - Immunoliposomes that optimize internationalization into target cells (2011-01-18),
2. 7507407 - Immunoliposomes that optimize internationalization into target cells (2009-03-24),
3. 7462603 - Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery (2008-12-09),
4. 7022336 - Methods for attaching proteins to lipidic microparticles with high efficiency (2006-04-04),
5. 6943027 - Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery (2005-09-13),
6. 6803053 - Lipidic microparticles linked to multiple proteins (2004-10-12),
7. 6528087 - Kits for forming protein-linked lipidic microparticles (2003-03-04),
8. 6426086 - pH-sensitive, serum-stable liposomes (2002-07-30),
9. 6410049 - Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery (2002-06-25),
10. 6214388 - Immunoliposomes that optimize internalization into target cells (2001-04-10),
11. 6210707 - Methods of forming protein-linked lipidic microparticles, and compositions thereof (2001-04-03),
12. 6071533 - Preparation of stable formulations of lipid-nucleic acid complexes for (2000-06-06),
13. 4806466 - Cell agglutination reagent comprising conjugates of antibody covalently (1989-02-21),
14. 4755388 - Liposome-encapsulated 5-fluoropyrimidines and methods for their use (1988-07-05),
15. 4598051 - Liposome conjugates and diagnostic methods therewith (1986-07-01),

Title: Demetrios P. Papahadjopoulos: Innovator in Immunoliposome Technology

Introduction: Demetrios P. Papahadjopoulos, based in San Francisco, CA, is a prominent inventor with a remarkable portfolio of 21 patents. His pioneering work primarily focuses on the development of immunoliposomes, which are innovative drug delivery systems aimed at optimizing the targeting and internalization of therapeutic agents into specific cells.

Latest Patents: Among his notable patents are advancements related to immunoliposomes that enhance drug internalization into target cells exhibiting unique cell surface markers. Specifically, his invention details the composition of immunoliposomes incorporating an Fab' domain from an antibody that binds to these markers, alongside amphipathic vesicle-forming lipids and polyethylene glycol-derivatised lipids. This innovative approach not only furthers the effectiveness of drug delivery but also introduces growth-inhibiting immunoliposomes capable of restricting cell growth and proliferation without relying on conventional growth-inhibiting therapeutic agents.

Career Highlights: Throughout his career, Papahadjopoulos has been associated with prestigious institutions, notably the University of California, where he contributed significantly to research and development. His expertise in liposomal technology and drug formulation has established him as a leading figure in his field.

Collaborations: He has collaborated with notable colleagues such as Keelung Hong and Weiwen Zheng, whose combined expertise has further bolstered advancements in immunoliposome applications and therapies. These collaborations have been crucial in evolving the landscape of targeted drug delivery.

Conclusion: Demetrios P. Papahadjopoulos continues to make significant strides in the realm of immunoliposome technology. His extensive patent portfolio and collaborative efforts reflect his commitment to innovation and improving therapeutic strategies in medicine. As research in this field progresses, his contributions will likely have a lasting impact on drug delivery systems and patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…